Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I
作者:Geng Sun、Yanping You、Haobin Li、Yalong Cheng、Ming Qian、Xinyu Zhou、Haoliang Yuan、Qing-Long Xu、Liang Dai、Pengfei Wang、Keguang Cheng、Xiaoan Wen、Caiping Chen
DOI:10.1016/j.ejmech.2020.112466
日期:2020.8
inhibition of mitochondrial complex I, leading to increased risk of lactic acidosis. In order to find novel AdipoRon analogues that activate AMPK without inhibition of complex I, 27 analogues of AdipoRon were designed, synthesized and biologically evaluated. As results, benzyloxy arylamide B10 was identified as a potent AMPK activator without inhibition of complex I. B10 dose-dependently improved glucose
AMPK的激活成为代谢疾病的潜在治疗方法。据称AdipoRon是一种脂联素受体激动剂,可通过脂联素受体1(AdipoR1)激活AMPK。但是,AdipoRon还显示出对线粒体复合体I的中等抑制作用,导致乳酸性酸中毒的风险增加。为了找到激活AMPK而不抑制复合物I的新型AdipoRon类似物,设计,合成和生物学评估了27种AdipoRon类似物。结果,苄氧基芳基酰胺B10被确定为有效的AMPK活化剂,而没有抑制复合物I。B10剂量依赖性地改善了正常小鼠的葡萄糖耐量,并显着降低了db / db糖尿病小鼠的空腹血糖水平并改善了其胰岛素抵抗。更重要的是,与泛AMPK激活剂MK-8722不同,B10不会引起心脏肥大,可能是由于其在肌肉组织而非心脏组织中选择性激活了AMPK。在一起,B10代表一类新的AMPK激活剂,具有抗代谢疾病的潜在治疗潜力。